Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06293950
PHASE1
Allogeneic Wharton Jelly Mesenchymal Stromal Cell (WJMSC) for Treatment of Autism
Sponsor: University of Jordan
View on ClinicalTrials.gov
Summary
Autism spectrum disorders (ASDs) are characterized by core domains: persistent deficits in social communication and interaction; restricted, repetitive patterns of behavior, interests, or activities.
Key Details
Gender
All
Age Range
4 Years - 14 Years
Study Type
INTERVENTIONAL
Enrollment
14
Start Date
2022-03-09
Completion Date
2027-12
Last Updated
2025-01-24
Healthy Volunteers
No
Conditions
Interventions
BIOLOGICAL
WJMSC
\- Patients receive three intravenous doses of MSCs (1 million/kg) every two weeks as treatment.
Locations (1)
Cell Therapy Center
Amman, Jordan